Pacira BioSciences had its Relative Strength (RS) Rating upgraded from 83 to 92 Monday.
IBD's proprietary rating tracks market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the last 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the best stocks often have an RS Rating of over 80 at the beginning of a new run.
How To Use Stock Charts To Stay Profitable And Protected
Pacira BioSciences is not currently offering a proper buying opportunity. See if the stock goes on to build a sound pattern that could spark a new run.
Pacira BioSciences reported 10% EPS growth in its most recent report, while sales growth came in at 3%. Keep an eye out for the company's next round of numbers on or around Feb. 27.
Pacira BioSciences earns the No. 12 rank among its peers in the Medical-Biomed/Biotech industry group. Halozyme Therapeutics, Catalyst Pharmaceuticals and Corcept Therapeutics are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
